Total Payments
$2,727
2023 Payments
$34.51
Companies
31
Transactions
194
Medicare Patients
1,407
Medicare Billing
$321,362
Payment Breakdown by Category
Food & Beverage$2,697 (98.9%)
Education$30.15 (1.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,697 | 188 | 98.9% |
| Education | $30.15 | 6 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $378.03 | 34 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $364.14 | 24 | $0 (2021) |
| Amgen Inc. | $278.52 | 18 | $0 (2021) |
| Genentech USA, Inc. | $257.04 | 21 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $179.78 | 15 | $0 (2020) |
| Exelixis Inc. | $126.06 | 14 | $0 (2017) |
| Janssen Biotech, Inc. | $102.28 | 7 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $89.33 | 5 | $0 (2021) |
| TESARO, Inc. | $81.81 | 4 | $0 (2019) |
| Kyowa Kirin, Inc. | $74.83 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $34.51 | 2 | Pharmacyclics LLC, An AbbVie Company ($34.51) |
| 2022 | $42.95 | 3 | Kite Pharma, Inc. ($28.90) |
| 2021 | $312.70 | 15 | Novartis Pharmaceuticals Corporation ($79.69) |
| 2020 | $103.23 | 7 | Amgen Inc. ($32.74) |
| 2019 | $408.54 | 23 | E.R. Squibb & Sons, L.L.C. ($124.67) |
| 2018 | $178.40 | 12 | Amgen Inc. ($45.83) |
| 2017 | $1,646 | 132 | Genentech USA, Inc. ($257.04) |
All Payment Transactions
194 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/14/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: ONCOLOGY | ||||||
| 03/03/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $14.59 | General |
| 01/04/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $14.31 | General |
| 07/15/2021 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: HEMATOLOGY | ||||||
| 07/09/2021 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI, JAKAFI | Food and Beverage | Cash or cash equivalent | $19.86 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 05/13/2021 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $22.35 | General |
| Category: Hematology/Oncology | ||||||
| 05/06/2021 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Hematology | ||||||
| 04/29/2021 | GENZYME CORPORATION | CABLIVI (Biological), SARCLISA | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Hematology | ||||||
| 04/28/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: Oncology | ||||||
| 03/11/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Oncology | ||||||
| 02/25/2021 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: HEMATOLOGY | ||||||
| 02/18/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.62 | General |
| Category: Oncology | ||||||
| 02/11/2021 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $25.70 | General |
| Category: Oncology | ||||||
| 01/28/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: ONCOLOGY | ||||||
| 01/07/2021 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR, TABRECTA | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2020 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Hematology | ||||||
| 10/15/2020 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Oncology | ||||||
| 09/10/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.71 | General |
| Category: Oncology | ||||||
| 03/10/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 155 | 176 | $49,365 | $13,588 |
| 2022 | 7 | 229 | 1,423 | $51,275 | $30,926 |
| 2021 | 13 | 443 | 21,886 | $147,148 | $82,196 |
| 2020 | 18 | 580 | 20,465 | $694,435 | $194,652 |
Total Patients
1,407
Total Services
43,950
Medicare Billing
$321,362
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 87 | 89 | $31,945 | $8,787 | 27.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 53 | 70 | $15,130 | $4,161 | 27.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 15 | 17 | $2,290 | $640.22 | 28.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 19 | 1,140 | $23,460 | $16,538 | 70.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 67 | 73 | $13,505 | $7,632 | 56.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 80 | $6,800 | $4,382 | 64.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 23 | $3,450 | $1,059 | 30.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 19 | 21 | $1,050 | $630.44 | 60.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 43 | $2,236 | $351.32 | 15.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 24 | 43 | $774.00 | $333.07 | 43.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 51 | 3,900 | $59,340 | $41,676 | 70.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2021 | 17 | 17,340 | $20,808 | $13,308 | 64.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 49 | 49 | $17,885 | $7,908 | 44.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 56 | 102 | $15,300 | $5,802 | 37.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 23 | $4,255 | $2,415 | 56.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 23 | 42 | $7,350 | $2,173 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 22 | $4,950 | $2,069 | 41.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 32 | $2,720 | $1,776 | 65.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $2,750 | $1,420 | 51.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 61 | 134 | $6,968 | $1,370 | 19.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 81 | 164 | $2,952 | $1,277 | 43.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 20 | 30 | $1,500 | $890.70 | 59.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 17 | 37 | $370.00 | $111.00 | 30.0% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2020 | 27 | 254 | $406,400 | $67,070 | 16.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 38 | 2,400 | $52,440 | $36,170 | 69.0% |
About Dr. Anthony Kalliath, MD
Dr. Anthony Kalliath, MD is a Hematology & Oncology healthcare provider based in Florence, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902989189.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Kalliath, MD has received a total of $2,727 in payments from pharmaceutical and medical device companies, with $34.51 received in 2023. These payments were reported across 194 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($2,697).
As a Medicare-enrolled provider, Kalliath has provided services to 1,407 Medicare beneficiaries, totaling 43,950 services with total Medicare billing of $321,362. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Florence, AL
- Active Since 10/23/2006
- Last Updated 04/24/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1902989189
Products in Payments
- OPDIVO (Biological) $317.48
- IMBRUVICA (Drug) $139.71
- TASIGNA (Drug) $135.79
- Avastin (Biological) $120.47
- KEYTRUDA (Biological) $106.18
- Neulasta (Biological) $102.66
- Cabometyx (Drug) $87.13
- GAZYVA (Biological) $78.97
- SANCUSO (Drug) $74.83
- Nplate (Biological) $71.20
- Abraxane (Drug) $66.16
- VOTRIENT (Drug) $64.78
- EMPLICITI (Biological) $60.55
- ELZONRIS (Drug) $58.75
- Tavalisse (Drug) $58.75
- TAGRISSO (Drug) $55.64
- Kyprolis (Biological) $55.62
- Xtandi (Drug) $50.61
- ZEJULA (Drug) $48.84
- EMEND (Drug) $48.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Florence
Dr. Mark Keaton, M.d, M.D
Hematology & Oncology — Payments: $30,744
Hematology & Oncology $30,744
Dr. Clint Kingsley, Md, MD
Hematology & Oncology — Payments: $21,594
Hematology & Oncology $21,594
Rajesh Bajaj, M.d, M.D
Hematology & Oncology — Payments: $18,826
Hematology & Oncology $18,826
Dr. Heather Brody
Hematology & Oncology — Payments: $10,048
Hematology & Oncology $10,048
Ravneet Bajwa, M.d, M.D
Hematology & Oncology — Payments: $4,477
Hematology & Oncology $4,477
James Smith, Md, MD
Hematology & Oncology — Payments: $2,684
Hematology & Oncology $2,684